SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddys Laboratories inform about press release

19 Mar 2020 Evaluate

Dr. Reddys Laboratories has informed that the company has enclosed a Press Release on March 19 2020 tilted ‘Dr. Reddy's Laboratories announces first-to-market launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Singledose Prefilled Syringe in the US Market.’

The above information is a part of company’s filings submitted to BSE. 

Dr. Reddys Labs. Share Price

1346.25 6.90 (0.52%)
02-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1871.55
Dr. Reddys Labs. 1346.25
Cipla 1456.25
Zydus Lifesciences 1099.65
Lupin 2398.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: